Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01291004 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives
A Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 206
- Enrollment target
NCT01291004: Completed Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT01291004 is a Phase 1 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 206 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (243% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01291004, a Phase 1 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 206 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the impact of a 28-day oral contraceptive compared to two 28-day oral contraceptive regimens containing different synthetic progestins on ovarian follicular activity and hormone levels in healthy women.
Interventions
- DRUG Desogestrel/ethinyl estradiol and ethinyl estradiol
- DRUG 28-day drospirenone oral contraceptive
- DRUG 28-day levonorgestrel oral contraceptive
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2011-01-31 |
| Est. Completion | 2012-03-31 |
| Phase | Phase 1 |
What the finished NCT01291004 record still lists
NCT01291004 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (243% higher).
The record links to 0 conditions, and to 3 interventions - of which Desogestrel/ethinyl estradiol and ethinyl estradiol is the first listed.
NCT01291004 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01291004 about?
NCT01291004 is a clinical study titled "A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives". This study is being conducted to evaluate the impact of a 28-day oral contraceptive compared to two 28-day oral contraceptive regimens containing different synthetic progestins on ovarian follicular activity and hormone levels in healthy women.
What is the current status of trial NCT01291004?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 206 participants. The study started on 2011-01-31. Estimated completion is 2012-03-31.
What interventions are being tested in trial NCT01291004?
The interventions under investigation include: Desogestrel/ethinyl estradiol and ethinyl estradiol (DRUG), 28-day drospirenone oral contraceptive (DRUG), 28-day levonorgestrel oral contraceptive (DRUG).
Who is sponsoring clinical trial NCT01291004?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01291004's enrollment target sits among peer trials
206 253rd of 2000 higher than 1,748 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI